Format

Send to

Choose Destination
Oncotarget. 2015 Jun 20;6(17):15464-81.

Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells.

Author information

1
Department of Medicine and Surgery, University of Salerno, Baronissi, Salerno, Italy.
2
Department of Pharmacy, University of Salerno, Fisciano, Salerno, Italy.
3
"G.Rummo" Medical Hospital, Department of Neurosurgery, Benevento, Italy.
4
Neurosurgery Unit A.O. San Giovanni di Dio e Ruggi d' Aragona - Salerno's School of Medicine, Largo Città di Ippocrate, Salerno, Italy.
5
Institute of Endocrinology and Experimental Oncology, IEOS CNR, Naples, Italy.
6
Department of Biology and Cellular and Molecular Pathology, University of Naples Federico II, Naples, Italy.

Abstract

Herein we show that a majority of human brain tumor samples and cell lines over-expressed cannabinoid receptor CB1 as compared to normal human astrocytes (NHA), while uniformly expressed low levels of CB2. This finding prompted us to investigate the therapeutic exploitation of CB1 inactivation by SR141716 treatment, with regard to its direct and indirect cell-mediated effects against gliomas. Functional studies, using U251MG glioma cells and primary tumor cell lines derived from glioma patients expressing different levels of CB1, highlighted SR141716 efficacy in inducing apoptosis via G1 phase stasis and block of TGF-β1 secretion through a mechanism that involves STAT3 inhibition. According to the multivariate role of STAT3 in the immune escape too, interestingly SR141716 lead also to the functional and selective expression of MICA/B on the surface of responsive malignant glioma cells, but not on NHA. This makes SR141716 treated-glioma cells potent targets for allogeneic NK cell-mediated recognition through a NKG2D restricted mechanism, thus priming them for NK cell antitumor reactivity. These results indicate that CB1 and STAT3 participate in a new oncogenic network in the complex biology of glioma and their expression levels in patients dictate the efficacy of the CB1 antagonist SR141716 in multimodal glioma destruction.

KEYWORDS:

CB1; MICA; NK cells; STAT3; gliomas

PMID:
26008966
PMCID:
PMC4558164
DOI:
10.18632/oncotarget.3895
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center